Key Details
Price
$66.30Annual ROE
3.51%Beta
0.68Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Oct 29, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%.
Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth.
SAN RAFAEL, Calif. , Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia.
UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PST SAN RAFAEL, Calif. , Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is the best option for those looking for undervalued stocks?
FAQ
- What is the primary business of BioMarin Pharmaceutical?
- What is the ticker symbol for BioMarin Pharmaceutical?
- Does BioMarin Pharmaceutical pay dividends?
- What sector is BioMarin Pharmaceutical in?
- What industry is BioMarin Pharmaceutical in?
- What country is BioMarin Pharmaceutical based in?
- When did BioMarin Pharmaceutical go public?
- Is BioMarin Pharmaceutical in the S&P 500?
- Is BioMarin Pharmaceutical in the NASDAQ 100?
- Is BioMarin Pharmaceutical in the Dow Jones?
- When was BioMarin Pharmaceutical's last earnings report?
- When does BioMarin Pharmaceutical report earnings?
- Should I buy BioMarin Pharmaceutical stock now?